Press Releases
08 Sep 2023
Xbrane announces that members of Xbrane’s management team have sold shares for tax purposes.
29 Aug 2023
XBRANE UPDATES AMBITION TO GENERATE POSITIVE OPERATING CASH FLOW ON AN MONTHLY BASIS BEFORE END OF FIRST QUARTER 2025
25 Aug 2023
Invitation to presentation of Xbrane Biopharma’s interim report January – June 2023 on August 29, 2023
21 Jun 2023
Xbrane announce U.S. FDA filing acceptance for a Lucentis® (ranibizumab) biosimilar candidate
15 Jun 2023
Xbrane strengthens its commitment to sustainable business by joining the United Nations Global Compact
29 May 2023
Correction: Invitation to presentation of Xbrane Biopharma’s interim report January – March 2023 on May 31, 2023
29 May 2023
Invitation to presentation of Xbrane Biopharma’s interim report January – March 2023 on May 31, 2023